Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; Results from the nationwide PCBaSe Sweden

European Journal of Clinical Pharmacology

Volumn 68, Issue 12, 2012, Pages 1619-1630

  Grundmark, B ^a,b,c   Garmo, H ^a,b,d   Zethelius, B ^a,c   Stattin, P ^e,f   Lambe, M ^b,g   Holmberg, L ^a,b,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adherence; Anti androgen; Bicalutamide; Medical possession ratio; Prostate cancer; SPDR

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; GONADORELIN DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; DATA BASE; DISEASE SEVERITY; DRUG APPROVAL; DRUG CHOICE; DRUG WITHDRAWAL; GLEASON SCORE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OFF LABEL DRUG USE; ORCHIECTOMY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER DATABASE SWEDEN; SWEDEN; TREATMENT PLANNING;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; DATABASES, FACTUAL; HUMANS; MALE; MEDICATION ADHERENCE; NITRILES; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS; SWEDEN; TOSYL COMPOUNDS;

EID: 84871348618     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1290-x     Document Type: Article

References (34)

1. Furr BJ, Tucker H (1996) The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 47(1A Suppl):13-25, discussion 29-32
2. Waller AS, Sharrard RM, Berthon P, Maitland NJ (2000) Androgen receptor localisation and turnover in human prostate epithelium treated with the anti-androgen, casodex. J Mol Endocrinol 24(3):339-351
3. Aronson JK (2007) Compliance, concordance, adherence. Br J Clin Pharmacol 63(4):383-384
4. Bardel A, Wallander MA, Svärdsudd K (2007) Factors associated with adherence to drug therapy: a population-based study. Eur J Clin Pharmacol 63(3):307-314
5. Williams AF, Manias E, Walker R (2008) Adherence to multiple, prescribed medications in diabetic kidney disease: a qualitative study of consumers' and health professionals' perspectives. Int J Nurs Stud 45(12):1742-1756
6. Lindberg MJ, Andersen SE, Christensen HR, Kampmann JP (2008) Compliance to drug prescriptions. Review. (in Danish). Ugeskr Laeger 170(22):1912-1916
7. D'Incà R, Bertomoro P, Mazzocco K et al (2008) Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther 27(2):166-172
8. Darkow T, Henk HJ, Thomas SKet al (2007) Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 25(6):481-496
9. Nilsson JL, Andersson K, Bergkvist A et al (2006) Refill adherence to repeat prescriptions of cancer drugs to ambulatory patients. Eur J Cancer Care 15(3):235-237
10. Atkins L, Fallowfield L (2006) Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42(14):2271-2276
11. Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602-606
12. Adolfsson J, Garmo H, Varenhorst E et al (2007) Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 41(6):456-477
13. Hagel E, Garmo H, Bill-Axelson A et al (2009) PCBaSe Sweden: a register-based resource for prostate cancer research. Scand J Urol Nephrol 43(5):342-349
14. SCB (2012) Statistics Sweden. http://www.scb.se
15. Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373
16. Berglund A, Garmo H, Tishelman C et al (2011) Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol 185(3):833-839
17. National Comprehensive Cancer Network (2012) Home page. http://www.nccn.com/cancer-guidelines.html
18. Wettermark B, Hammar N, Fored CM et al (2007) The new Swedish Prescribed Drug Register - opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16(7):726-735
19. Medical Products Agency (2003) Behandlingsrekommendation Behandling av prostatacancer (in Swedish/Norwegian). Behandlingsrekommendation Behandling av prostatacancer
20. National Board of Health and Welfare (2007) Nationella riktlinjerför prostatacancersjukvård (in Swedish). http://www.socialstyrelsen.se/ publikationer2007/2007-102-8)
21. Regional Cancer Centre of theUppsala-Örebro (2011), Prostate Cancer Treatment Guidelines (in Swedish). http://www.cancercentrum.se/uppsalaorebro/ vardprocesser/Prostatacancer/vardprogram/
22. World Health Organisation (2012) ATC/DDD index 2012. http://www.whocc.no/ atc-ddd-index/
23. Kalbfleisch DL, Prentice RL (2002) The statistical analysis of failure time data. Wiley, New York, pp 252-258
24. Andrade SE, Kahler KH, Frech F et al (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15:565-574
25. Vink NM, Klungel OH, Stolk RP, Denig P (2009) Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol Drug Saf 18(2):159-165
26. Hallas J, Gaist D, Bjerrum L (1997) The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. Epidemiology 8(6):666-670
27. Haynes RB, Taylor DW, Sackett DL (eds) (1979) Compliance in health care. Johns Hopkins University Press, Baltimore
28. Partridge AH, Avorn J, Wang PS, Winer EP (2002) Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94(9):652-661
29. Ziller V, Kalder M, Albert US et al (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20(3):431-436
30. Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120-4128
31. Güth U, Myrick ME, Kilic N, et al. Compliance and persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Res Treat 2011;131(2):491-499
32. Balkrishnan R (1998) Predictors of medication adherence in the elderly. ClinTher 20(4):764-771
33. Becker MH, Maiman LA (1975) Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care 13(1):10-24
34. Avorn J, Monette J, Lacour A et al (1998) Persistence of use of lipid-lowering medications: a cross-national study. JAMA 279(18):1458-1462